The sea or mariner's astrolabe
In: Agrupamento de Estudos de Cartografia Antiga 15 : Secção de Coimbra
In: Série Separatas
8 Ergebnisse
Sortierung:
In: Agrupamento de Estudos de Cartografia Antiga 15 : Secção de Coimbra
In: Série Separatas
In: Maritime monographs and reports 19
In: Environmental science & policy, Band 89, S. 365-377
ISSN: 1462-9011
This chapter provides an up-to-date review of the state of knowledge relating to the source of sediment and nutrients as well as pesticides and other pollutants delivered to the Great Barrier Reef from adjacent catchments. The strengths and limitations of the various datasets are also discussed. Collectively, sediment, nutrients, pesticides and other pollutants (e.g. petroleum hydrocarbons, pharmaceuticals) are described as 'pollutants'. This chapter is focused on defining the major source areas of these pollutants across the Great Barrier Reef, how these sources have varied in space and time, the major processes (e.g. hillslope, gully and streambank erosion) delivering these pollutants, their relative loads to the Great Barrier Reef and a summary of the main drivers in terms of land use, land condition and agricultural practices. Plot- and paddock-scale studies, including the effectiveness of remediation approaches, are summarised in Chapter 4. Acknowledging that all forms of data used to estimate pollutant loads to the Great Barrier Reef have constraints and limitations, this review uses a 'multiple lines of evidence' approach and draws on data from three main sources. These include the Queensland Government load monitoring data, the latest Queensland Government whole of Great Barrier Reef Source Catchments modelling results (which underpin the Report Card 2015) as well as a summary of the numerous individual research projects and synthesis reports published over the last four years. Data and information are included that was published, publicly available and that had undergone a peer review process. In a few cases, grey literature (e.g. consulting reports) and journal publications currently in review are included. A synthesis of the broad findings of this chapter are outlined below and in Table 1. A detailed description of what has changed since the last Scientific Consensus Statement is provided in Table 20.
BASE
BackgroundExperimental and clinical evidence supports the role of inflammation in atherosclerosis and its complications. Colchicine is an orally administered, potent antiinflammatory medication that is indicated for the treatment of gout and pericarditis.MethodsWe performed a randomized, double-blind trial involving patients recruited within 30 days after a myocardial infarction. The patients were randomly assigned to receive either low-dose colchicine (0.5 mg once daily) or placebo. The primary efficacy end point was a composite of death from cardiovascular causes, resuscitated cardiac arrest, myocardial infarction, stroke, or urgent hospitalization for angina leading to coronary revascularization. The components of the primary end point and safety were also assessed.ResultsA total of 4745 patients were enrolled; 2366 patients were assigned to the colchicine group, and 2379 to the placebo group. Patients were followed for a median of 22.6 months. The primary end point occurred in 5.5% of the patients in the colchicine group, as compared with 7.1% of those in the placebo group (hazard ratio, 0.77; 95% confidence interval [CI], 0.61 to 0.96; P = 0.02). The hazard ratios were 0.84 (95% CI, 0.46 to 1.52) for death from cardiovascular causes, 0.83 (95% CI, 0.25 to 2.73) for resuscitated cardiac arrest, 0.91 (95% CI, 0.68 to 1.21) for myocardial infarction, 0.26 (95% CI, 0.10 to 0.70) for stroke, and 0.50 (95% CI, 0.31 to 0.81) for urgent hospitalization for angina leading to coronary revascularization. Diarrhea was reported in 9.7% of the patients in the colchicine group and in 8.9% of those in the placebo group (P = 0.35). Pneumonia was reported as a serious adverse event in 0.9% of the patients in the colchicine group and in 0.4% of those in the placebo group (P = 0.03).ConclusionsAmong patients with a recent myocardial infarction, colchicine at a dose of 0.5 mg daily led to a significantly lower risk of ischemic cardiovascular events than placebo. (Funded by the Government of Quebec and others; COLCOT ClinicalTrials.gov number, NCT02551094.).
BASE
A risk assessment method was developed and applied to the Great Barrier Reef (GBR) to provide robust and scientifically defensible information for policy makers and catchment managers on the key land-based pollutants of greatest risk to the health of the two main GBR ecosystems (coral reefs and seagrass beds). This information was used to inform management prioritisation for Reef Rescue 2 and Reef Plan 3. The risk assessment method needed to take account of the fact that catchment-associated risk will vary with distance from the river mouth, with coastal habitats nearest to river mouths most impacted by poor marine water quality. The main water quality pollutants of concern for the GBR are enhanced levels of suspended sediments, excess nutrients and pesticides added to the GBR lagoon from the adjacent catchments. Until recently, there has been insufficient knowledge about the relative exposure to and effects of these pollutants to guide effective prioritisation of the management of their sources.
BASE